Press releases | WebDisclosure

Basculer en Français

11119	Companies
244820	Keywords
172890	Articles
132003	Press releases

Home
Press releases

PRESS RELEASE

published on 04/08/2024 at 23:30, 2 years 5 months ago

Inspire Veterinary Partners Reports Full Year 2023 Financial Results
Inspire Veterinary Partners, Inc. reports approximately 70% revenue growth year-over-year to $16.7M in 2023. Cost reduction initiatives and SG&A savings drive operational efficiency and profitability. Expansion in pet health sector remains promising

Revenue Growth Cost Reduction Initiatives Inspire Veterinary Partners Inc. Pet Health Sector SG&A Savings
PRESS RELEASE

published on 04/08/2024 at 23:25, 2 years 5 months ago

Guanajuato Silver Reports Year End 2023 Financial Results
Guanajuato Silver Company Ltd. announces financial and production results for 2023, showing record production and revenue growth. The Company continues to expand its operations in Mexico

Financial Information Guanajuato Silver Company Ltd. Silver Mines Production Results Record Revenue
PRESS RELEASE

published on 04/08/2024 at 23:20, 2 years 5 months ago

Ur-Energy Announces Appointment of New Board Members: John Paul Pressey and Elmer W. Dyke
Ur-Energy Inc. appoints John Paul Pressey and Elmer W. Dyke as new Board members, announces retirement of James M. Franklin and W. William Boberg. Company expresses gratitude towards retiring Directors

Board Members Ur-Energy Inc. Leadership Transition Retirement Nuclear Power
PRESS RELEASE

published on 04/08/2024 at 23:15, 2 years 5 months ago

Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
Data4Cure announces the release of the Single-Cell Immune Checkpoint Inhibition Atlas at AACR 2024, facilitating insights on cancer immunotherapy. CEO highlights integration of high-throughput data for new therapies

Cancer Research Immunotherapy AACR 2024 Data4Cure Single-cell Atlas
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 5 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 5 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. La société publie ses résultats opérationnels et financiers pour l’exercice clos le 31 décembre 2023, mettant en avant ses avancées dans le développement de traitements pour les maladies liées à l'âge

Résultats Financiers Biophytis Développement Clinique Maladies Liées À L'âge Traitements
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 5 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 5 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024

Biophytis Étude Clinique BIO101 Obésité OBA
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 5 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 5 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial

Accesswire

Published on 10/03/2026 at 02:35, 2 days 1 hour ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 2 days 10 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 2 days 14 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 2 days 15 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 2 days 15 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/05/2026 at 00:05, 4 hours 18 minutes ago

TerraMaster lance sa saison de mise à niveau du stockage avec jusqu’à 30 % de réduction à l’occasion des Prime Big Deal Days
Published on 10/04/2026 at 06:05, 22 hours 17 minutes ago

Blokees Debuts 90+ New Products at Wonder Festival Shanghai 2026
Published on 10/04/2026 at 05:15, 23 hours 7 minutes ago

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Published on 10/03/2026 at 15:45, 1 day 12 hours ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 2 days 4 hours ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY

Les Echos

Published on 10/02/2026 at 17:45, 2 days 10 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 2 days 10 hours ago

Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 2 days 10 hours ago

Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 2 days 10 hours ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/02/2026 at 17:30, 2 days 10 hours ago

Aéroports de Paris SA - Calendrier financier 2027

View all LES ECHOS COMFI WIRE